Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans

Hermann E Wasmuth ¹, Frank Lammert , Mirko Moreno Zaldivar

⁰Department of Medicine III, University Hospital Aachen, Aachen, Germany. hwasmuth@ukaachen.de

Gastroenterology +

|

April 7, 2009

View abstract on PubMed

Summary

This study reveals that the chemokine CXCL9 and its receptor CXCR3 play a protective role against liver fibrosis. Modulating CXC chemokine levels may offer new antifibrotic therapies for chronic liver diseases.

Area Of Science

Immunology
Gastroenterology
Molecular Biology

Background

Liver fibrosis is a critical feature of chronic liver diseases with incompletely understood mechanisms.
Chemokines are key mediators of inflammation, and their genes are linked to fibrogenesis.
The roles of CXCL9 and its receptor CXCR3 in liver fibrosis require investigation.

Purpose Of The Study

To investigate the function of the chemokine CXCL9 and its receptor CXCR3 in the context of liver fibrosis.
To determine the antifibrotic potential of the CXCL9-CXCR3 pathway.

Main Methods

Analysis of CXCL variants in hepatitis C patients and CXCR3(-/-) mice with induced fibrosis.
Assessment of intrahepatic immune cells and interferon gamma mRNA levels in mice.
Measurement and correlation of human serum CXCL9 levels with fibrosis severity.
In vitro studies on human hepatic stellate cells (LX-2) stimulated with CXCL9.

Main Results

Specific CXCL9 variants were linked to liver fibrosis in both mice and humans.
CXCL9 demonstrated in vitro antifibrotic effects by suppressing collagen production in LX-2 cells.
CXCR3(-/-) mice exhibited exacerbated liver fibrosis, associated with reduced Th1 immune responses.

Conclusions

This research identifies a novel chemokine-based antifibrotic pathway in the liver.
Targeting CXC chemokine levels presents a potential therapeutic strategy for liver fibrosis.
The CXCL9-CXCR3 axis is crucial for regulating Th1-associated immune pathways in liver fibrosis.

Related Concept Videos